Feline Hypertrophic Cardiomyopathy: ACVIM Staging, Diagnosis, and Evidence-Based Management

Bottom line

• Hypertrophic cardiomyopathy (HCM) is the most common cardiac disease of adult cats, affecting roughly 1 in 7 (prevalence ~14–15%), and is the leading cause of feline cardiac morbidity and mortality. The hallmark lesion is concentric — often asymmetric — left ventricular hypertrophy producing diastolic dysfunction, with systolic function preserved until late disease.
• Stage the disease with the ACVIM 2020 consensus (A–D). Most cats present preclinical (B1/B2) and may remain so for years; across a ~10-year horizon roughly 15–25% progress to congestive heart failure (CHF) and ~10% develop arterial thromboembolism (ATE) [1][2].
• Echocardiography remains the diagnostic gold standard (maximal LV wall thickness ≥6 mm in diastole after excluding secondary causes); NT-proBNP and cardiac troponin I (cTnI) are useful primary-care screening and progression-monitoring adjuncts but do not replace echo [1][2].
• Clopidogrel is the evidence-based thromboprophylactic of choice for cats at increased ATE risk (moderate-to-severe left atrial enlargement, spontaneous echocardiographic contrast [SEC], low LA appendage velocity, low LA fractional shortening). It is superior to aspirin for secondary prevention (FAT CAT), and aspirin is no longer recommended first-line [1][3][4]. As of July 2026 the absolute benefit is real but moderate (see the efficacy section) [5].
• No drug has been shown to delay progression from preclinical to clinical HCM. Cardiac myosin inhibitors (mavacamten, aficamten) and rapamycin are active in cats but have no veterinary approval as of early 2025 [2].
• This is a clinician-facing evidence summary, not a treatment protocol. Confirm drug dosing, staging thresholds, and monitoring intervals against current formularies and cardiologist guidance.

Drug facts

Clopidogrel (antiplatelet — thromboprophylaxis, the load-bearing drug in HCM)

• Class / MOA: Thienopyridine P2Y12 ADP-receptor antagonist; irreversibly inhibits ADP-mediated platelet aggregation. Prodrug requiring hepatic activation.
• Primary indication: Thromboprophylaxis in cats at increased ATE risk and secondary prevention after a cardiogenic ATE event. First-line antiplatelet per ACVIM 2020 [1].
• Evidence tier: ACVIM Level of Evidence medium, based primarily on the FAT CAT randomized trial [1][4].
• Approval status: No feline-labeled product; used off-label from human formulations, typically compounded.
• Contraindications / precautions: Active hemorrhage or high bleeding risk; caution around surgery/invasive procedures. Palatability is a practical barrier — cats find the tablet bitter; compounding into capsules or use of pill pockets is usually required for reliable dosing and adherence [4].
• Combination use: For very high-risk cats, ACVIM permits adding low-dose aspirin OR an oral factor Xa inhibitor to clopidogrel, at low level of evidence [1][3].

Aspirin (antiplatelet — superseded)

• Class / MOA: Non-selective COX inhibitor; irreversibly blocks thromboxane A2–mediated platelet aggregation.
• Status: No longer recommended as first-line thromboprophylaxis. Inferior to clopidogrel in FAT CAT; the 2024 Guillaumin review states aspirin is not recommended in the acute or chronic setting [3][4].

Acute-FATE pharmacotherapy (supportive backbone)

• Analgesia: Opioids are standard (FATE is among the most painful feline emergency presentations); butorphanol is an alternative [3].
• Anticoagulation: Heparin to limit clot propagation during the acute event [3].
• Thrombolysis: Tissue plasminogen activator (tPA), e.g. the BLASTT protocol, can accelerate limb reperfusion in selected survivors but carries significant hemorrhagic risk (including fatal intracranial hemorrhage); an advanced intervention for equipped centers only [3].
• Adjuncts (limited evidence): Cilostazol (PDE-III inhibitor, antiplatelet + possible vasodilation) and flunarizine (calcium-channel blocker used for vasodilation in some European centers) — discussed for collateral flow, weak evidence [3].

Emerging disease-modifying agents (no veterinary approval as of early 2025) [2]

• Cardiac myosin inhibitors — mavacamten, aficamten: Modulate the actin–myosin cross-bridge cycle to reduce hypercontractility (approved in humans for symptomatic obstructive HCM). Feline pharmacologic activity demonstrated — including acute LVOTO reduction with mavacamten in a small prospective case series of MYBPC3-positive cats, and an acceptable single-dose safety profile for aficamten — but no approved veterinary product and no chronic feline dosing data.
• Rapamycin (mTOR inhibitor): Early evidence of HCM lesion reversal in cats. As of early 2025 a pivotal study across ~20 US sites enrolling ~300 cats was reported underway, with FDA conditional approval anticipated. Confirm enrollment criteria, dosing, and monitoring with a cardiologist or trial coordinator.

Efficacy — how much does clopidogrel actually protect? (contested)

The efficacy of clopidogrel is the most nuanced question in feline HCM thromboprophylaxis, because the pivotal trial reported a relative benefit in a secondary-prevention population, while most clinical prescribing is primary prevention. Both readings below are legitimate; they answer different questions.

The trial finding (relative benefit, secondary prevention). FAT CAT (Hogan et al., 2015) was a multicenter, double-blind, randomized, positive-controlled trial in cats that had survived at least one cardiogenic ATE and been stable ≥1 month, randomized to clopidogrel vs low-dose aspirin [4]. On the composite primary endpoint (time to recurrent CATE or cardiac death), clopidogrel-treated cats had a markedly longer median time to event — 346 days (95% CI 146–495) vs 128 days (95% CI 58–243) with aspirin — and lower recurrence (48% vs 75%), a relative risk reduction of ~35%. Both drugs were well tolerated with no dose-related toxicity. These data drove the ACVIM 2020 recommendation for clopidogrel [1][4].

The re-analysis (absolute benefit, primary prevention). A 2024 JAVMA viewpoint by Rishniw re-framed the same data for the scenario clinicians face most — cats with moderate-to-severe HCM who have not yet had an ATE [5]. It rests on two stated assumptions: that the secondary-prevention effect transfers to primary prevention (clinically assumed but unproven), and that aspirin has little/no effect on feline ATE (supported by earlier uncontrolled series). Applying the ~35% relative reduction to a ~10% baseline ATE risk yields an absolute risk reduction of roughly 3–4%, i.e. a number needed to treat of ~23–29 cats to prevent one ATE event. Crucially, the viewpoint does not argue against clopidogrel — it argues for honest client conversations about a moderate effect size and the administration burden.

Neutral synthesis. There is no genuine conflict of fact: FAT CAT establishes clopidogrel > aspirin (large relative and median-time-to-event benefit) in secondary prevention, and Rishniw quantifies what that means in absolute terms for the more common primary-prevention decision (modest ARR, NNT ~23–29). The two are complementary. Practical reconciliation: clopidogrel is the correct antiplatelet choice; expected benefit scales with baseline risk, so it is strongest in the highest-risk cats (severe LA enlargement, SEC, prior ATE), and the counseling emphasis shifts toward realistic expectations and adherence in lower-risk cats.

Comparators — clopidogrel vs aspirin vs combinations

• Clopidogrel vs aspirin: Clopidogrel is superior for secondary ATE prevention (FAT CAT). Aspirin monotherapy is no longer recommended first-line [3][4].
• Combination antiplatelet/anticoagulant: For very high-risk cats, ACVIM allows clopidogrel plus low-dose aspirin OR an oral factor Xa inhibitor, at low level of evidence — a considered escalation, not a default [1][3].
• Head-to-head with factor Xa inhibitors: No feline RCT establishes superiority of a factor Xa inhibitor over clopidogrel; combination is the guideline-sanctioned use, reserved for the highest-risk patients [1][3].

Safety and adverse effects

• Clopidogrel / aspirin tolerability: In FAT CAT both antiplatelets were well tolerated with no identified dose-related toxicity; the principal real-world limitation of clopidogrel is palatability/adherence rather than organ toxicity [4].
• Heparin (acute FATE): Bleeding risk with anticoagulation; monitor accordingly [3].
• tPA thrombolysis: Significant hemorrhagic risk including fatal intracranial hemorrhage, plus reperfusion injury (hyperkalemia, acidosis) as ischemic limbs reperfuse — reserve for equipped centers with intensive monitoring and explicit client counseling [3].
• Reperfusion monitoring: After any reperfusion (spontaneous or induced), monitor for the metabolic consequences of ischemia-reperfusion during acute FATE management [3].

Special populations and scenarios

• Breed-predisposed cats: Maine Coon, Ragdoll, British Shorthair, Scottish Fold, Sphynx, Persian. The best-characterized sarcomeric mutations are MYBPC3 A31P (Maine Coon) and MYBPC3 R820W (Ragdoll) — autosomal dominant, incomplete penetrance, variable expressivity. Commercial genetic tests exist for these two; a negative test does not exclude HCM, and the causal mutation for most non-breed-specific HCM remains unidentified [2].
• Acute FATE presentation: Grave acute prognosis — roughly 30–50% of cats die or are euthanized at presentation; >90% have underlying cardiomyopathy (HCM predominant). Poor-outcome predictors include bilateral limb involvement, hypothermia, and CHF. Structured prognostic counseling at presentation — acute survival odds, likelihood of functional limb recovery, the underlying cardiac disease, and the long-term thromboprophylaxis commitment — is as important as immediate medical management, and euthanasia is a legitimate choice where welfare concerns dominate [3].
• Cats with LVOTO / SAM: Dynamic left ventricular outflow tract obstruction (worsened by tachycardia, dehydration, sympathetic tone), associated with systolic anterior motion of the mitral valve. Symptomatic LVOTO and any systolic dysfunction warrant cardiology referral [1].
• CHF stage (C/D): Management centers on furosemide-based diuresis for the underlying cardiomyopathy; no antiplatelet substitutes for CHF therapy [2].

Multimodal and diagnostic work-up

• Diagnostic standard: Echocardiography — maximal LV wall thickness ≥6 mm (IVS or LV free wall, diastole) in a cat of appropriate body size, after excluding secondary causes [1][2].
• Exclude secondary causes first: Systemic hypertension (direct Doppler blood pressure), hyperthyroidism (total T4), and significant aortic stenosis before diagnosing HCM [1].
• Emerging imaging (Beier 2025): Speckle-tracking echocardiography (myocardial strain imaging) can detect subclinical diastolic/systolic dysfunction before conventional criteria are met; contrast echocardiography improves characterization of SEC and LA thrombus [2].
• Biomarkers: NT-proBNP (SNAP Feline proBNP or laboratory assay) flags apparently healthy cats likely to have echocardiographic disease and triages referral; cTnI marks cardiomyocyte injury and carries prognostic weight. Neither replaces echocardiography [1][2].
• Risk stratification for ATE: LA enlargement (LA:Ao ≥1.5), SEC/"smoke," and reduced LA appendage velocity are the principal echocardiographic predictors and drive the thromboprophylaxis decision [1].

Contraindications, precautions & PK

• Clopidogrel is a hepatically activated thienopyridine prodrug (irreversible P2Y12 blockade; antiplatelet effect persists for the platelet lifespan after dosing stops). Avoid or use with caution in active hemorrhage, coagulopathy, or the perioperative window; plan a washout before elective invasive procedures per current guidance. The dominant clinical limitation is palatability-driven non-adherence — compound into capsules or use pill pockets [4].
• Aspirin irreversibly inhibits COX/thromboxane; cats have limited glucuronidation and slow salicylate clearance, narrowing the margin — a further reason it has fallen out of first-line use beyond its inferior efficacy [3][4].
• Heparin / tPA carry bleeding risk; tPA additionally carries intracranial-hemorrhage and reperfusion-injury risk [3].
• Dosing note: Specific milligram doses, frequencies, and washout intervals are intentionally not asserted here — confirm against a current veterinary formulary and cardiologist guidance, as the authored evidence base above establishes drug choice and effect size, not a dosing protocol.

Practical decision support

1. Confirm the diagnosis echocardiographically and exclude secondary causes (hypertension, hyperthyroidism, aortic stenosis) [1].
2. Stage with ACVIM 2020: A (breed risk, no structural disease) → B1 (echo HCM, no hemodynamic compromise) → B2 (HCM with LA enlargement, LA:Ao ≥1.5) → C (current/prior CHF) → D (refractory CHF) [1].
3. Stratify ATE risk by LA size and function (moderate-to-severe LA enlargement, SEC, low LA appendage velocity, low LA FS%) [1].
4. Start clopidogrel for at-risk cats; do not use aspirin first-line. Reserve combination antiplatelet/factor Xa strategies for the highest-risk cats, at low level of evidence [1][3][4].
5. Counsel realistically: clopidogrel reduces but does not eliminate ATE risk (NNT ~23–29 in primary prevention); benefit is greatest in the highest-risk cats; proactively address palatability/adherence [4][5].
6. Set a monitoring cadence: follow-up echocardiography every 6–12 months for stable preclinical disease, more frequently as disease advances; refer for initial staging, symptomatic LVOTO, or systolic dysfunction [1].
7. For acute FATE: prioritize aggressive analgesia (opioids), heparin, warming, judicious fluids, and reperfusion monitoring; consider tPA only in equipped centers; frame prognosis (30–50% acute mortality) and present euthanasia as a legitimate option [3].
8. Manage expectations on progression: no drug delays preclinical→clinical progression; emphasize that many HCM cats remain preclinical for years; track emerging myosin-inhibitor and rapamycin trial data [2].

Always confirm specific drug dosing, diagnostic thresholds, and monitoring intervals against current formularies and board-certified cardiologist guidance.

Frequently Asked Questions

What is the first-line thromboprophylactic for cats with HCM at risk of ATE? Clopidogrel. The ACVIM 2020 consensus recommends it (Level of Evidence: medium) for cats with moderate-to-severe LA enlargement, SEC, low LA appendage velocity, or low LA FS%, based on the FAT CAT trial. Aspirin is no longer recommended as first-line [1][4].

Is clopidogrel actually better than aspirin in cats, or is that assumed? It is trial-established for secondary prevention. In FAT CAT (Hogan 2015), clopidogrel extended median time to recurrent ATE or cardiac death to 346 vs 128 days and reduced recurrence to 48% vs 75% with aspirin [4].

How much does clopidogrel actually reduce ATE risk in absolute terms? For primary prevention, a 2024 JAVMA re-analysis (Rishniw) estimates ~3–4% absolute risk reduction (NNT ~23–29) — applying FAT CAT's ~35% relative reduction to a ~10% baseline risk in moderate-to-severe HCM. The benefit is real but moderate and largest in the highest-risk cats [5].

What are the echocardiographic criteria for diagnosing feline HCM? Maximal LV wall thickness ≥6 mm in diastole (IVS or LV free wall) in a cat of appropriate body size, after excluding secondary causes such as systemic hypertension, hyperthyroidism, and aortic stenosis. Echocardiography remains the diagnostic gold standard [1][2].

How should I acutely manage a cat with aortic thromboembolism (FATE)? Prioritize aggressive analgesia (opioids), heparin anticoagulation, external warming, judicious fluid support, and reperfusion monitoring. tPA thrombolysis can accelerate reperfusion in selected survivors but carries major hemorrhagic risk and is for equipped centers only. Acute mortality is ~30–50% [3].

Do NT-proBNP and troponin I replace echocardiography for HCM? No. NT-proBNP flags apparently healthy cats likely to have echocardiographic disease and triages referral; cTnI marks cardiomyocyte injury and carries prognostic weight. Both are screening/monitoring adjuncts, not a substitute for echocardiographic diagnosis and staging [1][2].

Are there approved disease-modifying drugs (mavacamten, aficamten, rapamycin) for feline HCM? Not as of early 2025. Cardiac myosin inhibitors (mavacamten, aficamten) and rapamycin show pharmacologic activity in cats — including acute LVOTO reduction with mavacamten and early lesion-reversal signals for rapamycin — but none is approved for veterinary use; rapamycin was in a pivotal US trial. Confirm trial eligibility with a cardiologist [2].

What proportion of HCM cats progress to heart failure or thromboembolism? Over roughly a 10-year horizon, about 15–25% develop CHF and about 10% develop ATE. Most cats present in preclinical (B1/B2) stages and may remain there for years [1][2].

Does a negative breed genetic test rule out HCM? No. Commercial tests exist for MYBPC3 A31P (Maine Coon) and R820W (Ragdoll), but a negative result does not exclude HCM, and the causal mutation for most non-breed-specific feline HCM remains unidentified [2].

Changelog

• 2026-07-06: Consolidated three dated dispatch posts into this evergreen hub — folded in the FAT CAT trial with the 2024 Rishniw absolute-benefit re-analysis (efficacy/comparators), the Guillaumin 2024 JFMS acute-FATE and thromboprophylaxis review (special populations, safety), and the Beier 2025 Vet Sci review of diagnostic advances and emerging therapies (myosin inhibitors, rapamycin, strain imaging). Reorganized evidence by clinical question and added a decision-support workflow.
• 2026-07-03: First published.